

# Calzada Ltd

AusBiotech Conference  
19<sup>th</sup> October 2011

David Franklyn  
Chairman  
0402 447 839  
[dfranklyn@calzada.com.au](mailto:dfranklyn@calzada.com.au)



#### Top Shareholders

1. Entrust Investment Fund 17.2%
2. Fleming SG Capital 8.4%
3. Senior Management 7.5%
4. Joint Venture Partners 1.5%

# Calzada

ASX Code : CZD

Share Price: 6.2 cents

Market Cap: \$21.5m

Cash: \$6.8m (August 2011)

## PolyNovo

Laurent Fossaert

Owns NovoSorb™, a suite of biodegradable polymers used in medical devices and as a tissue scaffold

## Metabolic

David Kenley

Owns AOD9604, a peptide proven safe in human trials with activity in fat reduction and bone health

David Franklyn

Chairman

0402 447 839

dfranklyn@calzada.com.au



# PolyNovo Lead Projects

- **NovoSorb™ BTM** - developing a “step change” treatment for full thickness burns:
  - NovoSorb™ provides a biodegradable temporizing matrix (BTM) scaffold to allow dermal tissue growth, ready for skin graft (or CCS)
- **License agreement with Smith & Nephew** targeting fracture fixation and bone void filler applications
  - Innovative treatments of orthopaedic trauma
  - Early stage in-vivo studies commenced
- **Collaboration with a major global medical device company in a new field**
  - Received \$US 300,000 in milestone based payments so far in calendar 2011
  - Potential to move to license negotiations in future



David Franklyn  
Chairman  
0402 447 839  
[dfranklyn@calzada.com.au](mailto:dfranklyn@calzada.com.au)



# PolyNovo's NovoSorb™ BTM

- **Project Status**

- Completed preclinical studies (28 pigs) with results exceeding expectations
- Safety studies (ISO 10993) due for completion in Q4 2011
- Ethics committee approval for human trials received
- Pilot human trial expected to start Q4 2011
- A/Prof John Greenwood awarded the inaugural American Burns Association Burke Yannis prize

- **Product Advantages**

- Preclinical studies showed rapid tissue integration, under 10 days compared to current industry norm of 21 days
- Ability to apply split skin graft immediately on BTM, creating multiple product opportunities
- Reduction in wound contraction superior to best in class product (Integra)
- Improved resistance to infection or mechanical failure (common in current treatments)
- Easy to manufacture and cost competitive
- Easy to use, should result in better uptake by Surgeons



David Franklyn  
Chairman  
0402 447 839  
[dfranklyn@calzada.com.au](mailto:dfranklyn@calzada.com.au)



# Metabolic

- **Looking to unlock value from AOD9604. The compound;**
  - has extensive safety data from previous trials
  - Is being manufactured now in China and USA (in contravention of our patents)
  - has demonstrated some activity in weight reduction in humans
  - when tested in animal models has demonstrated bone anabolic and anti-resorptive activity
  - when tested in human stem cell assays has demonstrated bone mineralisation
- **Identified key opportunities within clear time frames and tight cost constraints:**
  - Licensed to Phosphagenics (POH) for use in a cellulite cream (BodyShaper <sup>TM</sup>) and future cosmetics and now generating revenue
  - Investigating non-drug regulatory path to market as OTC product: cheaper and quicker path to market
  - Assembling comprehensive safety pack together with in vivo and in vitro bone test results
- **For a modest capital outlay we are targeting major markets with large unmet demand for a product solution**



David Franklyn  
Chairman  
0402 447 839  
[dfranklyn@calzada.com.au](mailto:dfranklyn@calzada.com.au)



# Calzada Value Proposition

- Market capitalisation of \$21.5m with over 2 years cash (\$6.8m August 2011)
- The next six months will provide clear insight into the commercial potential of our technologies; in particular:
  - PolyNovo's first human trial for Novosorb™ BTM planned for Q4 2011
  - PolyNovo's collaboration with a major medical device company concludes in December 2011, potentially leading to license negotiations
  - Further progress with Smith & Nephew on fracture fixation and bone void filler applications
  - Market response to Phosphagenics' BodyShaper™ product will be evident
  - Greater clarity on AOD9604 neutraceutical and bone health opportunities

David Franklyn  
Chairman  
0402 447 839  
dfranklyn@calzada.com.au

